Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panbio Ltd.

www.panbio.com

Latest From Panbio Ltd.

In Vitro Diagnostics: The Quest For Growth

This article first appeared in Medtech Insight, October 2010.
Medical Device

In Vitro Diagnostics: The Quest for Growth

The global economic downturn has put pressure on large, consumer-based in vitro diagnostic markets, such as diabetes glucose-testing, driving down sales, pricing, and profits. As a result, the IVD industry is actively seeking out higher growth opportunities to offset this impact-and it is finding solutions in several areas, branching into underserved emerging markets like China and India and targeting higher-growth clinical segments such as cancer, women's health, and infectious disease. But perhaps the biggest opportunity for future growth lies in the field of molecular diagnostics, particularly products that address the move toward more personalized care. Suppliers well positioned to take advantage of this opportunity are likely to experience strong growth ahead.
Medical Device Platform Technologies

Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q1 2008

The first quarter of 2008 saw a dearth in financings for both the medical device and in vitro diagnostics segments. In the former, volume fell short of the billion dollar mark while the latter failed to reach the success the previous quarter had witnessed, despite completing an equal number of transactions. M&A in medical devices didn't look any more promising, bringing in $1.6 billion, a huge slide from the impressive $10 billion total of 2007's fourth quarter. However, there was one bright spot: acquisitions within in vitro diagnostics/research reagents substantially increased to $3.1 billion from the $370 million spent in the previous three months, led by Inverness Medical Innovations' $1.1 billion takeover of Matria Healthcare Inc. Also noteworthy: oncology diagnostics alliances grew slowly and steadily thanks to increasing attention from larger companies.
BioPharmaceutical Medical Device

Business & Technology Briefs (11/2007)

Brief summaries of recent product and company developments in the device industry, including: poor acceptance dooms Exubera inhaled insulin; QLT bets big on ForSight plug; hot markets, lukewarm IPOs; Arteriocyte Medical launches; Synthes buys N Spine.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Alias(es)
  • PanBio Pty. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Panbio Ltd.
  • Senior Management
  • Stuart Hazell, PhD, CEO
    Peter Burrows, VP, Admin. & CFO
    Greg Hafner, PhD, VP, R&D
    John Moylan, VP, Sales & Mktg.
  • Contact Info
  • Panbio Ltd.
    Phone: (61) 7 3363 7100
    532 Seventeen Mile Rocks Rd.
    Windsor
    Sinnamon Park, 4073
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register